FDA warning letter
Issue date
16 Oct 2020
Issuing office
Division of Pharmaceutical Quality Operations I
Posted date
24 Nov 2020
Subject
CGMP/Finished Pharmaceuticals/Adulterated
Products & Services
Drugs
Aurolife Pharma
Manufacturer
Warning letter
Headquarters
United States of AmericaSites
United States of America